At the news
? NEUTRALIMPACT 3/10 8-K filed Jul 23, 2026 at 19:54 ET
Outlook Therapeutics granted stock options to its CEO (100,000 options) and CFO (210,078 options) at $1.4304/share, vesting in July 2027, and approved cash bonuses of $420,000 (CEO) and $200,000 (CFO) contingent on FDA approval of ONS-5010 by July 31, 2026. This is a routine compensatory arrangement tied to the BLA process, not a departure or material change in leadership, and carries no immediate financial impact for shareholders beyond the potential cash payout if the FDA milestone is met within days.
- CEO Robert C. Jahr received 100,000 stock options at $1.4304/share, vesting July 21, 2027.
- CFO Lawrence A. Kenyon received 210,078 stock options at $1.4304/share, vesting July 21, 2027.
- CEO awarded a cash bonus opportunity of $420,000, payable only if FDA approves ONS-5010 by July 31, 2026.
- CFO awarded a cash bonus opportunity of $200,000, payable only if FDA approves ONS-5010 by July 31, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access